| Autor: |
Xi, Wang, Cheng-Sheng, Zhang, Xu-Yuan, Dong, Yuan, Hu, Bao-Jun, Duan, Jun, Bai, Yin-Ying, Wu, Lin, Fan, Xin-Hua, Liao, Ye, Kang, Peng, Zhang, Meng-Yang, Li, Jiao, Xu, Zhi-Jun, Mao, Hui-Tong, Liu, Xiao-Long, Zhang, Li-Fei, Tian, En-Xiao, Li |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
World Journal of Gastrointestinal Oncology. 14:1252-1264 |
| ISSN: |
1948-5204 |
| DOI: |
10.4251/wjgo.v14.i7.1252 |
| Popis: |
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed and treated in advanced tumor stages with poor prognosis. More effective screening programs and novel therapeutic means are urgently needed. Recent studies have regarded tight junction protein claudin 18.2 (CLDN18.2) as a candidate target for cancer treatment, and zolbetuximab (formerly known as IMAB362) has been developed against CLDN18.2. However, there are few data reported thus far related to the clinicopathological characteristics of CLDN18.2 expression for PDAC.To investigate the expression of CLDN18.2 in PDAC patients and subsequently propose a new target for the treatment of PDAC.The Cancer Genome Atlas, Genotype-Tissue Expression, Gene Expression Omnibus, and European Genome-phenome Archive databases were first employed to analyze theThe gene expression ofCLDN18.2 expression is frequently increased in PDAC patients. Thus, it may act as a potential therapeutic target for zolbetuximab in PDAC. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
